Óskare Capital

Óskare Capital is a venture investment firm headquartered in Paris and London that specializes in early-stage investments primarily in the Deeptech and Life Sciences sectors, with a strong focus on the medical cannabinoid industry. Their mission centers on backing innovative companies with disruptive technologies and strong barriers to entry, particularly in areas like synthetic biology, biopharmaceuticals, and digital health. Óskare Capital supports startups that address significant health challenges such as chronic pain, addiction, and brain diseases, thereby impacting the startup ecosystem by fostering cutting-edge solutions in health and sustainability[1][2][4].

Founded in the late 2010s, Óskare Capital emerged to capitalize on the growing scientific and medical acceptance of cannabinoid-based therapies in Europe. The firm was officially launched with the creation of Óskare Fund I, a regulated investment vehicle designed to provide investors access to innovative European companies in medical cannabinoids and related fields. Key partners include CEO Alexandre Ouimet-Storrs and a senior advisory board that brings deep expertise and network strength. The firm has evolved from focusing solely on cannabinoid-related ventures to a broader life sciences and deeptech investment approach, maintaining a hands-on style that combines capital injection with strategic business support and partnership facilitation[2][3].

Core Differentiators

• Specialized Focus: Concentrates on medical cannabinoids and adjacent life sciences sectors, leveraging deep domain expertise.
• Regulated Fund Structure: Operates through an AIFM-compatible fund regulated by the Central Bank of Ireland, ensuring transparency and investor protection.
• Hands-on Support: Beyond capital, provides business insights and introductions to strategic partners, accelerating portfolio company growth.
• Strong Network: Supported by a senior advisory board with extensive industry experience, enhancing deal sourcing and value creation.
• Early-Stage Expertise: Invests at pre-seed, seed, and early growth stages, enabling influence on company trajectory from inception[1][2][3].

Role in the Broader Tech Landscape

Óskare Capital rides the wave of increasing acceptance and scientific validation of cannabinoid-based medical treatments, a trend driven by regulatory changes and growing healthcare needs such as chronic pain management and addiction treatment. The timing is critical as Europe and the UK expand their medical cannabis markets, creating fertile ground for innovation in pharmaceuticals, synthetic biology, and digital health solutions. By focusing on disruptive technologies with strong barriers to entry, Óskare Capital positions itself at the intersection of healthcare innovation and sustainable biotech, influencing the broader ecosystem by enabling startups that could redefine treatment paradigms and bio-based product markets[1][2][4].

Quick Take & Future Outlook

Looking ahead, Óskare Capital is likely to deepen its investment footprint in medical cannabinoids while expanding into adjacent life sciences and deeptech innovations. Trends such as personalized medicine, digital therapeutics, and sustainable biotech will shape their portfolio evolution. Their influence may grow as they continue to provide not only capital but also strategic guidance and network access, helping startups scale in a highly regulated and rapidly evolving sector. This positions Óskare Capital as a pivotal player in driving the next generation of health and biotech breakthroughs in Europe and beyond[1][2][3].